Regeneron Pharmaceuticals Inc (REGN)
Current ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Total current assets | US$ in thousands | 18,660,900 | 19,479,200 | 15,884,100 | 14,014,900 | 12,753,900 |
| Total current liabilities | US$ in thousands | 3,944,300 | 3,423,400 | 3,141,300 | 3,932,500 | 2,806,800 |
| Current ratio | 4.73 | 5.69 | 5.06 | 3.56 | 4.54 |
December 31, 2024 calculation
Current ratio = Total current assets ÷ Total current liabilities
= $18,660,900K ÷ $3,944,300K
= 4.73
The current ratio of Regeneron Pharmaceuticals Inc has been consistently healthy over the years, indicating the company's ability to meet its short-term obligations using its current assets. As of December 31, 2020, the current ratio was 3.63, slightly decreasing to 3.56 by December 31, 2021. However, there was a significant improvement in the ratio by December 31, 2022, reaching 5.06, which further increased to 5.69 by December 31, 2023. Although there was a slight decrease to 4.73 by December 31, 2024, the current ratio still remains at a level that indicates a strong liquidity position for Regeneron Pharmaceuticals Inc. This consistent trend suggests the company's ability to manage its short-term financial obligations effectively.
Peer comparison
Dec 31, 2024